Foghorn Therapeutics (NASDAQ:FHTX) versus Valneva (NASDAQ:VALN) Head to Head Contrast

Foghorn Therapeutics (NASDAQ:FHTX) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Foghorn Therapeutics and Valneva”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$36.74 million	3.31	-$74.28 million	($0.98)	-2.09
Valneva	$197.56 million	2.79	-$130.33 million	($2.11)	-2.75

Foghorn Therapeutics has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Foghorn Therapeutics and Valneva, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1	5	4	0	2.30
Valneva	2	0	1	0	1.67

Foghorn Therapeutics currently has a consensus price target of $6.67, indicating a potential upside of 226.00%. Valneva has a consensus price target of $9.30, indicating a potential upside of 60.07%. Given Foghorn Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Foghorn Therapeutics is more favorable than Valneva.

Profitability

This table compares Foghorn Therapeutics and Valneva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-175.78%	N/A	-31.17%
Valneva	-110.33%	-153.20%	-39.50%

Volatility & Risk

Foghorn Therapeutics has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Valneva has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.

Insider & Institutional Ownership

61.5% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Foghorn Therapeutics beats Valneva on 11 of the 14 factors compared between the two stocks.

About Foghorn Therapeutics

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.